Core Insights - The current economic downturn is causing market demand to shrink and competition to intensify, leading over 40% of companies to experience revenue decline and profit compression, making the construction of core competitive barriers a key issue for the industry [1][2][3] - Only 17% of companies are able to establish sustainable core competitive barriers, while 65% struggle with growth due to insufficient barriers [2][3] - The article identifies five marketing strategy consulting firms with core competitive capabilities, based on a comprehensive evaluation of over 200 cross-industry companies [1][2][5] Economic Downturn and Challenges - Companies are facing a "growth pressure, homogenization, and difficulty in breaking through" dilemma, with 78% of enterprises having similar products, services, and marketing models, leading to a significant drop in average profit margins from 18% to 9% [2][3] - Many companies' advantages are easily replicable, with an average barrier lifespan of less than three years, making them vulnerable to competitors [3] - 62% of companies have strategic plans for building barriers but lack executable paths, resulting in over 50% waste of consulting fees [3] Key Points for Building Core Competitive Barriers - Companies should focus on precise positioning to uncover unique core values and avoid homogenization [4] - Resource integration is essential to create a multi-dimensional composite barrier combining technology, brand, and user collaboration [4] - Establishing a closed-loop system from strategic planning to execution and effect review is crucial for ensuring the implementation of barriers [4] - Companies need to concentrate resources on core advantages and reduce non-core business lines to strengthen their competitive foundation [4] - A dynamic iteration mechanism should be established to monitor and optimize barriers in response to market changes [5] Top 5 Consulting Firms - **Qizheng Muggu** ranks first, with 33 years of experience and a service network covering over 300 companies, helping clients build competitive barriers with an average lifespan of over 8 years and a customer repurchase rate of 88% [6][7] - **Hanpu Consulting** specializes in digital transformation, focusing on enhancing operational efficiency through digital tools [12] - **Xinhua Xin** is known for its market research and strategic consulting, providing solid market data support for barrier construction [13] - **iResearch Consulting** offers rich industry data resources, helping companies predict market trends and support barrier construction [14] - **McKinsey** is recognized for its global resource integration and macro-strategic planning capabilities, assisting large enterprises in building global competitive barriers [15][16]

Core Viewpoint - The control change at Kanghua Biotech, led by its actual controller Wang Zhentao, signifies the potential disintegration of the vaccine empire he built, as both of his listed companies face significant challenges [1][8]. Group 1: Company Performance and Challenges - Kanghua Biotech, once a high-flying stock, saw its share price peak at 996 yuan, with a market cap exceeding 17.8 billion yuan, but has since faced a decline due to falling performance and increased competition [2]. - The company's core product, the human diploid rabies vaccine, accounts for over 97% of its revenue, but its market position is being eroded by competitors like Kangtai Biotech, which achieved a first-year issuance of 3.37 million doses, nearly matching Kanghua's 3.89 million doses, a year-on-year drop of 43.83% [4]. - In 2024, Kanghua Biotech's revenue is projected to decline by 9.23%, while sales expenses are expected to rise by 10.68% to 547 million yuan, and R&D investment has been cut by 47.81% [5]. Group 2: Financial and Governance Issues - The net profit attributable to the parent company plummeted from 829 million yuan in 2022 to 20.7 million yuan in Q1 2025, a staggering year-on-year drop of 86.14% [6]. - Wang Zhentao's other business, Aokang International, has also faced significant losses, with cumulative losses exceeding 670 million yuan from 2022 to 2024, and a projected loss of 87 million yuan in the first half of 2025 [6]. - High equity pledge rates are concerning, with Wang Zhentao's stake in Kanghua Biotech pledged at 89.20%, and Aokang Group's stake at 71.91%, indicating financial strain [2][3]. Group 3: Strategic Moves and Future Outlook - To address its reliance on a single product, Kanghua Biotech is attempting to expand internationally by licensing the development of a six-valent norovirus vaccine, with a potential transaction value of 270 million USD, although clinical trials have not yet commenced [7]. - The transition of control at Kanghua Biotech reflects broader trends in the industry, where the lack of core competitive advantages leads to the unraveling of previously successful cross-industry ventures [8].